Cargando…

Completion pneumonectomy is safe and effective in select patients with recurrent non-small cell lung cancer

BACKGROUND: Locoregional recurrence rates for non-small cell lung cancer (NSCLC) remain high, even following curative surgical resection. While national guidelines advocate surgical resection for locoregional recurrence, it is rarely offered when resection would require completion pneumonectomy, whi...

Descripción completa

Detalles Bibliográficos
Autores principales: White, Abby, Kucukak, Suden, Lee, Daniel N., Bueno, Raphael, Jaklitsch, Michael, Mentzer, Steven, Sugarbaker, David, Wee, Jon, Swanson, Scott J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139098/
https://www.ncbi.nlm.nih.gov/pubmed/32274087
http://dx.doi.org/10.21037/jtd.2020.01.51
_version_ 1783518690889695232
author White, Abby
Kucukak, Suden
Lee, Daniel N.
Bueno, Raphael
Jaklitsch, Michael
Mentzer, Steven
Sugarbaker, David
Wee, Jon
Swanson, Scott J.
author_facet White, Abby
Kucukak, Suden
Lee, Daniel N.
Bueno, Raphael
Jaklitsch, Michael
Mentzer, Steven
Sugarbaker, David
Wee, Jon
Swanson, Scott J.
author_sort White, Abby
collection PubMed
description BACKGROUND: Locoregional recurrence rates for non-small cell lung cancer (NSCLC) remain high, even following curative surgical resection. While national guidelines advocate surgical resection for locoregional recurrence, it is rarely offered when resection would require completion pneumonectomy, which available literature associates with a 12–36% perioperative mortality and 40–80% morbidity. Additionally, survival advantages to radical surgery in this scenario are largely unknown, particularly because available series often include patients undergoing completion pneumonectomy for benign indications or metastatic disease from other primary sites, making extrapolation to primary lung cancer patients challenging. As systemic therapy options continue to evolve, particularly as it relates to immunotherapy, we expect that there will be more and more opportunities for locoregional surgical control. The aim of this study was to evaluate outcomes following completion pneumonectomy for recurrent NSCLC. METHODS: We retrospectively reviewed all patients who underwent completion pneumonectomy for recurrent NSCLC at our institution between 2000 and 2015. Factors affecting perioperative morbidity and mortality, as well as overall survival, were analyzed. RESULTS: Between 2000 and 2015, 28 patients underwent completion pneumonectomy for recurrent lung cancer (14 female, 14 male). The median age was 64.2 years (range, 36.7–84.0). There were 11 left-sided and 17 right-sided operations. Fourteen patients (50.0%) underwent chemotherapy or chemoradiotherapy prior to surgery. Perioperative morbidity was seen in 13 of 28 (46.4%) patients, and atrial fibrillation was the most common complication. Mortality at 30- and 90-day intervals was 3.6%, and 14.3% respectively. Five-year overall survival was 43.1% and was not associated with preoperative chemotherapy or chemoradiotherapy use. Patients over 70 years old (n=5) experienced a statistically higher rate of postoperative complications (100.0% vs. 34.8%, P=0.013), and this translated into a higher mortality rate at 60 and 90 days. Left-sided resections were associated with increased risk of recurrent laryngeal nerve injury (RLN) compared to right-sided resections (36.4% vs. 0%, P=0.016), and those patients with RLN injury were more likely to be reintubated (50.0% vs. 4.2%, P=0.04). Bronchopleural fistula occurred in 1 patient (3.6%). CONCLUSIONS: Completion pneumonectomy is a viable treatment option for patients with recurrent NSCLC. We attribute our low risks of major morbidity, such as bronchopleural fistula, to careful patient selection and technique. In patients over 70 years, morbidity is higher which should inform discussion regarding surgical options.
format Online
Article
Text
id pubmed-7139098
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-71390982020-04-09 Completion pneumonectomy is safe and effective in select patients with recurrent non-small cell lung cancer White, Abby Kucukak, Suden Lee, Daniel N. Bueno, Raphael Jaklitsch, Michael Mentzer, Steven Sugarbaker, David Wee, Jon Swanson, Scott J. J Thorac Dis Original Article BACKGROUND: Locoregional recurrence rates for non-small cell lung cancer (NSCLC) remain high, even following curative surgical resection. While national guidelines advocate surgical resection for locoregional recurrence, it is rarely offered when resection would require completion pneumonectomy, which available literature associates with a 12–36% perioperative mortality and 40–80% morbidity. Additionally, survival advantages to radical surgery in this scenario are largely unknown, particularly because available series often include patients undergoing completion pneumonectomy for benign indications or metastatic disease from other primary sites, making extrapolation to primary lung cancer patients challenging. As systemic therapy options continue to evolve, particularly as it relates to immunotherapy, we expect that there will be more and more opportunities for locoregional surgical control. The aim of this study was to evaluate outcomes following completion pneumonectomy for recurrent NSCLC. METHODS: We retrospectively reviewed all patients who underwent completion pneumonectomy for recurrent NSCLC at our institution between 2000 and 2015. Factors affecting perioperative morbidity and mortality, as well as overall survival, were analyzed. RESULTS: Between 2000 and 2015, 28 patients underwent completion pneumonectomy for recurrent lung cancer (14 female, 14 male). The median age was 64.2 years (range, 36.7–84.0). There were 11 left-sided and 17 right-sided operations. Fourteen patients (50.0%) underwent chemotherapy or chemoradiotherapy prior to surgery. Perioperative morbidity was seen in 13 of 28 (46.4%) patients, and atrial fibrillation was the most common complication. Mortality at 30- and 90-day intervals was 3.6%, and 14.3% respectively. Five-year overall survival was 43.1% and was not associated with preoperative chemotherapy or chemoradiotherapy use. Patients over 70 years old (n=5) experienced a statistically higher rate of postoperative complications (100.0% vs. 34.8%, P=0.013), and this translated into a higher mortality rate at 60 and 90 days. Left-sided resections were associated with increased risk of recurrent laryngeal nerve injury (RLN) compared to right-sided resections (36.4% vs. 0%, P=0.016), and those patients with RLN injury were more likely to be reintubated (50.0% vs. 4.2%, P=0.04). Bronchopleural fistula occurred in 1 patient (3.6%). CONCLUSIONS: Completion pneumonectomy is a viable treatment option for patients with recurrent NSCLC. We attribute our low risks of major morbidity, such as bronchopleural fistula, to careful patient selection and technique. In patients over 70 years, morbidity is higher which should inform discussion regarding surgical options. AME Publishing Company 2020-03 /pmc/articles/PMC7139098/ /pubmed/32274087 http://dx.doi.org/10.21037/jtd.2020.01.51 Text en 2020 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
White, Abby
Kucukak, Suden
Lee, Daniel N.
Bueno, Raphael
Jaklitsch, Michael
Mentzer, Steven
Sugarbaker, David
Wee, Jon
Swanson, Scott J.
Completion pneumonectomy is safe and effective in select patients with recurrent non-small cell lung cancer
title Completion pneumonectomy is safe and effective in select patients with recurrent non-small cell lung cancer
title_full Completion pneumonectomy is safe and effective in select patients with recurrent non-small cell lung cancer
title_fullStr Completion pneumonectomy is safe and effective in select patients with recurrent non-small cell lung cancer
title_full_unstemmed Completion pneumonectomy is safe and effective in select patients with recurrent non-small cell lung cancer
title_short Completion pneumonectomy is safe and effective in select patients with recurrent non-small cell lung cancer
title_sort completion pneumonectomy is safe and effective in select patients with recurrent non-small cell lung cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139098/
https://www.ncbi.nlm.nih.gov/pubmed/32274087
http://dx.doi.org/10.21037/jtd.2020.01.51
work_keys_str_mv AT whiteabby completionpneumonectomyissafeandeffectiveinselectpatientswithrecurrentnonsmallcelllungcancer
AT kucukaksuden completionpneumonectomyissafeandeffectiveinselectpatientswithrecurrentnonsmallcelllungcancer
AT leedanieln completionpneumonectomyissafeandeffectiveinselectpatientswithrecurrentnonsmallcelllungcancer
AT buenoraphael completionpneumonectomyissafeandeffectiveinselectpatientswithrecurrentnonsmallcelllungcancer
AT jaklitschmichael completionpneumonectomyissafeandeffectiveinselectpatientswithrecurrentnonsmallcelllungcancer
AT mentzersteven completionpneumonectomyissafeandeffectiveinselectpatientswithrecurrentnonsmallcelllungcancer
AT sugarbakerdavid completionpneumonectomyissafeandeffectiveinselectpatientswithrecurrentnonsmallcelllungcancer
AT weejon completionpneumonectomyissafeandeffectiveinselectpatientswithrecurrentnonsmallcelllungcancer
AT swansonscottj completionpneumonectomyissafeandeffectiveinselectpatientswithrecurrentnonsmallcelllungcancer